In late April 2021, FDA approved Farxiga for the treatment of CKD. The approval was based on results from the DAPA-CKD Ph3 trial which demonstrated a highly impressive 39% RRR in the primary composite endpoint (sustained ≥50% decline in eGFR, ESKD, renal death, or CV death; previous FENIX insight). Below, FENIX provides thoughts on the new Farxiga CKD indication, including read-through to finerenone, sotagliflozin, Jardiance and the rest of the SGLT2i class.